Systematic review – alopecia areata and tofacitinib in paediatric patients-Reference-Cited by-同舟云学术

Systematic review – alopecia areata and tofacitinib in paediatric patients

Published:2022-04-03 Issue:2 Volume:41 Page:194-201
ISSN:1556-9527
Container-title:Cutaneous and Ocular Toxicology
language:en
Short-container-title:Cutaneous and Ocular Toxicology

Author:

Bandeira António¹,Albino-Teixeira António¹,Magina Sofia¹²

Affiliation:

1. Unit of Pharmacology & Therapeutics, Department of Biomedicine, Faculty of Medicine, CIM-FMUP Centro de Investigação Médica da UP Rua Plácido da Costa, University of Porto, Porto, Portugal

2. Dermatology and Venereology Department, São João Hospital Center, EPE, Porto, Portugal

Publisher

Informa UK Limited

Subject

Toxicology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/15569527.2022.2084622

Reference39 articles.

1. Alopecia areata and health-related quality of life: a systematic review and meta-analysis

2. Understanding autoimmunity of vitiligo and alopecia areata

3. The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Tofacitinib, a Janus Kinase Inhibitor, in Humans

4. Sublingual tofacitinib for alopecia areata: a roll‐over pilot clinical trial and analysis of pharmacokinetics

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and efficacy of tofacitinib in 97 alopecia areata patients;Journal of Cosmetic Dermatology;2024-05-12

2. The Renin-Angiotensin System: The Challenge behind Autoimmune Dermatological Diseases;Diagnostics;2023-11-07

3. Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway;Indian Dermatology Online Journal;2023

4. Alopecia areata. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 2: Treatment;PRZ DERMATOL;2023